Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT-EHA CAR-T 2019 | CAR-T19: A novel model of recognition

Jürgen Kuball • 8 Mar 2019
EBMT-EHA CAR-T 2019
Acute Lymphoblastic Leukemia B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Leukemia Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma CAR-T

Jürgen Kuball MD, PhD, from the University Medical Center, Utrecht, Amsterdam, discusses the mode of recognition of T-cells engineered to express γδT cell receptor (TEGs), and the way in which this receptor (γδT) allows for the recognition of cancer cells via there early metabolic changes. Recorded at the 1st European CAR T-Cell Meeting in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).

More from Jürgen Kuball

1:12
Dual targeting of the cancer metabolome & stress antigens to improve efficacy of engineered T-cells
Jürgen Kuball • 17 Feb 2024
1:16
An update on the GoCART initiative: GoCART passports & new edition of the EBMT-EHA CAR-T handbook
Jürgen Kuball • 17 Feb 2024
0:48
Novel off-the-shelf CARs: where may these agents fit in the hemonc treatment landscape?
Jürgen Kuball • 10 Feb 2023
0:49
The promise of novel multivalent gamma-delta T-cells in the treatment of cancers
Jürgen Kuball • 10 Feb 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals